DUOVIR tablet is a consist of coordination of both drugs lamivudine and zidovudine, which exist to the nucleoside associated to class of antiretroviral drugs. Each tablet of DUOVIR consist of half of the commonly recommended daily doses of both lamivudine and zidovudine. With the availability of this consolidation of tablet, patients may be better able to comply to complex drug treatment medications, thereby increase compliance.
Lamivudine & Zidovudine
150mg & 300mg
Duovir tablet contains two nucleoside analogues combination which is indicated for the treatment in concomitant use with other antiretrovirals to treat human immunodeficiency virus type – 1 infection (HIV-1).
Lamivudine belongs to synthetic nucleoside analogue. Intracellularly, lamivudine is introducing a phosphate group to its active 5΄-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The primary mode of action of 3TC-TP is prohibition of reverse transcriptase (RT) via DNA chain termination after adding of the nucleoside analogue.
Zidovudine also belongs to synthetic nucleoside analogue and the action is like lamivudine. Intracellularly, zidovudine is introducing a phosphate group to its active 5΄-triphosphate metabolite, zidovudine triphosphate (ZDV-TP). The primary mode of action of ZDV-TP is inhibition of RT via DNA chain termination after fusion of the nucleotide analogue.
Fastly absorbed from the GI tract. Absorption with food is delayed and duration to high plasma concentration: Approx. 1 hr. Bioavailabilityof: 80-87% (Lamivudine); approx 60-70% (zidovudine).
Passes through blood-brain barrier and placenta whichget into breast milk and observe in semen (zidovudine). Volume of distribution: 1.3 L/kg (Lamivudine); 1-2.2 L/kg (zidovudine). Bounding to Plasma protein: Up to 36% (Lamivudine); 34-38% (zidovudine).
Both drugs are metabolized inner the cells to form the active triphosphate. Zidovudine undergoes hepatic metabolism, mostly to the inactive glucuronide.
Lamivudine and zidovudine eliminated Via urine, (primary as unchanged drug) Elimination of drugs has half-life: 5-7 hr. (Lamivudine); 0.5-3 hr (zidovudine).
Duovir Dosage and administration
The recommended Duovir dosage in adults is lamivudine 150mg and zidovudine 300mg with weight of >30kg one tablet twice in a day.
The pediatric dose for 14-21 kg one half tablet bid and for 22-30kg one half tablet in the morning or one half tab tid. Duovir may be taken with or without food.
While taking Duovir If any of these side effects occurs , you should consult with doctor urgently.
Chills, fever, pale skin, sore throat weakness, head pain
stomach ache, nausea, skin rash, vomiting, yellow eyes, coughing, l Loss of appetite, sleeping trouble
Incident not known
blurred vision, dry mouth, hair loss, increased (hunger,thirst,urination), chest discomfort, wheezing, myalgia, convulsions.
Monitoring Parameters ,Monitor haematological parameters observe for appearance of hardened infections and signs and symptoms of pancreatitis. Periodically check liver function test and for several month following discontinuation of therapy for patients co-infected with hepatitis B virus and HIV.
Obese women with hepatomegaly, hepatitis or other risk factors causes liver disease and hepatic steatosis; hepatitis B or C virus co-infection leads risk factors for pancreatitis Patient with poor bone marrow reserve before the treatment. Renal and severe hepatic impairment. Children Pregnancy.